| Document |
Document Title |
|
WO/2023/046715A1 |
The present invention generally relates to the use of a mulberry extract to improve sleep quality and/or subsequent behavioural outcomes. More particularly, the present disclosure relates to administration of a supplement comprising a mu...
|
|
WO/2023/042902A1 |
The present invention relates to a promoter for differentiation into a cartilage cell, a cartilage cell propagation promoter, and a cartilage matrix production promoter that contain a liquiritigenin glycoside. The present invention can...
|
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/042158A1 |
Uses of anamorelin for improving patient reported outcomes in anorexia / cachexia patients, particularly based on patient populations who benefit from such use, and methods for defining and providing clinically meaningful treatment effects.
|
|
WO/2023/042851A1 |
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates ...
|
|
WO/2023/043444A1 |
Methods and compositions for treating cancer (e.g., ovarian, fallopian tube, uterine, cervical, vaginal, vulvar, or peritoneal cancer) are disclosed. The methods include intermittent administration of a glucocorticoid receptor modulator ...
|
|
WO/2023/042876A1 |
A problem addressed is to provide a double-stranded nucleic acid complex with reduced central nervous system toxicity. Provided is a double-stranded nucleic acid complex including a first nucleic acid strand and a second nucleic acid s...
|
|
WO/2023/042888A1 |
The present invention provides a pharmaceutical composition for treating cognitive decline. The pharmaceutical composition includes an AMPA receptor antagonist. The present invention also provides a pharmaceutical composition for treatin...
|
|
WO/2023/038088A1 |
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt ...
|
|
WO/2023/039500A1 |
The present invention relates to compositions and local delivery methods to increase pelvic tissue integrity and the treatment, reduction and/or prevention of stress urinary incontinence [SUI | and fecal incontinence [FI] due to weakness...
|
|
WO/2023/039522A1 |
The present disclosure relates to a conjugate comprising a fatty acid moiety and a nucleic acid moiety wherein the fatty acid moiety is conjugated to the nucleic acid via a polyethylene glycol (PEG) and a glutamic acid group. The nucleic...
|
|
WO/2023/036148A1 |
Provided in the present invention are a cationic lipid compound and the use thereof, which relate to the field of biomedicines. A lipid nanoparticle prepared from the cationic lipid compound as represented by formula I in the present inv...
|
|
WO/2023/038027A1 |
The purpose of the present invention is to provide a screening method that enables efficient discovery of a novel senolytic drug and a senolytic drug obtained by the screening method. The present invention pertains to a senolytic drug ...
|
|
WO/2023/038068A1 |
The present invention provides a pharmaceutical composition for preventing or treating interstitial cystitis/bladder pain syndrome, the pharmaceutical composition containing an inhibitor against at least one type of integrin selected fro...
|
|
WO/2023/038118A1 |
A skin composition comprising extracellular vesicles derived from malted rice.
|
|
WO/2023/038481A1 |
The present invention relates to a heteroaryl derivative compound having STAT3 inhibitory activity, and a use thereof. The heteroaryl derivative compound according to the present invention exhibits excellent STAT3-selective inhibitory ac...
|
|
WO/2023/039171A1 |
Compositions and methods are disclosed herein for the treatment of aging frailty with bone marrow derived mesenchymal stem cells. The methods of treatment involve the administration of a composition of bone marrow derived mesenchymal ste...
|
|
WO/2023/039187A1 |
The present disclosure is directed to methods of improving the therapeutic effectiveness and safety profile of ibogaine for the treatment of conditions including, but not limited to, alcoholism, substance abuse disorder, and opioid use d...
|
|
WO/2023/038039A1 |
The present invention provides a medicine characterized by the combination of: a compound represented by (A) or a pharmaceutically acceptive salt thereof; and (B) at least one drug selected from the group consisting of drugs having exhib...
|
|
WO/2023/039405A1 |
The present disclosure is generally directed to compositions and methods related to USP15 inhibitors. More particularly, the present disclosure relates to methods of regulating CRL4CRBN-USP15 pathway (previously referred to as the CRL4CR...
|
|
WO/2023/033151A1 |
The present invention provides an osteoarthritis progression inhibitor containing, as active ingredients, a G-protein-coupled receptor kinase 5 inhibitor and hyaluronic acid or a pharmaceutically acceptable salt thereof. The G-protein-co...
|
|
WO/2023/033025A1 |
A plasmid transfection agent that comprises a peptide containing an amino acid sequence represented by SEQ ID NO: 1. SEQ ID NO: 1: CXDXXXXYXC (wherein: X represents an arbitrary amino acid residue; C represents cysteine; D represents a...
|
|
WO/2023/031387A1 |
Anoperineal lesions (APLs) are frequent in Crohn's disease and are particularly difficult to treat because of the induced tissue destruction and their recurrence. Now, the inventors developed the first preclinical model of perianal fistu...
|
|
WO/2023/034898A1 |
This invention relates to methods and compositions for inhibiting fibrosis and the formation of scars, e.g., as a result of corneal wounds, by administering NBL1 to a subject. The invention further relates to methods and compositions for...
|
|
WO/2023/032957A1 |
[Problem] To provide a pharmaceutical composition for the prevention and/or treatment of cancer. [Solution] Provided is a pharmaceutical composition for administration to a subject having CXCR1+CD14+ monocytes, the pharmaceutical composi...
|
|
WO/2023/030687A1 |
The present invention relates to the use of CYCLOPENTA[4,5]FURO[3,2-C]PYRIDINE derivatives of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders. The present invention relates fur...
|
|
WO/2023/031218A1 |
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
|
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
|
WO/2023/032955A1 |
In one embodiment, the present invention provides an antibody specifically binding to human GH, or an antigen-binding fragment thereof. In one embodiment, the present invention pertains to an antibody specifically binding to human GH, or...
|
|
WO/2023/033679A1 |
(Azacycloalkyl)methoxy-substituted benzamides of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1) are disclosed. The method for producing the compounds of for...
|
|
WO/2023/034530A1 |
Disclosed herein are methods of increasing production of interferon gamma (IFNγ) or activation or proliferation of immune cells using a CB2R modulator.
|
|
WO/2023/034615A1 |
Disclosed are methods for treatment of neurodegenerative diseases or inhibiting the progression of neurodegenerative disease. The methods may comprise inhibiting cellular dysfunctionality and subsequent cell death due to cellular accumul...
|
|
WO/2023/033174A1 |
This phytin has improved solubility in water. The present application provides a phytin that contains calcium and/or magnesium at a specific mole ratio with respect to phytic acid.
|
|
WO/2023/033681A1 |
Disclosed are substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1). The method for producing the compou...
|
|
WO/2023/032726A1 |
This cyclic peptide or salt thereof comprises either the amino acid sequence indicated in SEQ ID NO: 1, or an amino acid sequence obtained by deleting or substituting the amino acid of the N-terminus and/or the amino acid of the C-termin...
|
|
WO/2023/034265A1 |
Methods of treating pharyngeal airway collapse (e.g., sleep apnea) by administering a norepinephrine reuptake inhibitor (NRI) in combination with mandibular advancement device (MAD) therapy are described herein. The treatment may further...
|
|
WO/2023/032987A1 |
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...
|
|
WO/2023/033534A1 |
The KAI1 protein or a fragment thereof according to the present invention inhibited hepatic fibrosis in mice in which acute hepatic fibrosis was induced by CCl4. The KAI1 protein suppressed hepatic fibrosis by inhibiting fibrosis of hepa...
|
|
WO/2023/033098A1 |
The present invention provides a compound that exhibits an inhibitory activity against coronavirus 3CL protease or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. A compound represented by...
|
|
WO/2023/033680A1 |
7-Substituted 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1) are disclosed. The method for producing the compou...
|
|
WO/2023/032788A1 |
Provided are a protective agent, a surfactant composition, a composition for blood sugar level control, an autophagy inducing agent, a stain for mycobacteria, or a protein extraction agent characterized by containing a compound represent...
|
|
WO/2023/028513A1 |
Provided herein are pharmaceutical compositions (e.g., formulations) that can provide for the long-term stability of AAV vectors. Also provided herein are methods of making and using the pharmaceutical compositions. The pharmaceutical co...
|
|
WO/2023/024552A1 |
Disclosed in the present invention are a recombinant type-I humanized collagen polypeptide, and a preparation method therefor and the use thereof. The recombinant type-I humanized collagen polypeptide provided by the present invention co...
|
|
WO/2023/026957A1 |
Provided is an agent for the prevention and/or treatment of Porphyromonas gingivalis infection. An agent for the prevention and/or treatment of Porphyromonas gingivalis infection that contains killed Enterococcus faecalis. An agent for t...
|
|
WO/2023/026794A1 |
[Problem] To provide: a composition that suppresses mature-hepatocyte transdifferentiation or a composition that is capable of treating cholangiocarcinoma; and a screening method for substances for suppressing mature-hepatocyte transdiff...
|
|
WO/2023/027082A1 |
The present invention addresses the problem of providing a hybrid liposome exosome or the like capable of delivering an active ingredient to a target cell at a higher concentration. This peptide-bound hybrid liposome exosome, which inc...
|
|
WO/2023/027132A1 |
The present invention provides: a bone metabolic cell modulator including at least one polypeptide selected from the group consisting of Chromosome 4 Open Reading Frame 48 (C4orf48), C4orf48 variants having at least one among the ability...
|
|
WO/2023/001234A9 |
A modified small interfering RNA (siRNA) molecule comprising phosphorothioate (PS) intemucleotide linkages in the antisense strand for reducing off-target effects and methods and uses thereof. The siRNAs targeting Hypoxia Inducible Facto...
|
|
WO/2023/023994A1 |
A drug for improving the chemotaxis of anti-inflammatory macrophages and the use thereof in the preparation of a drug for improving the chemotaxis of anti-inflammatory macrophages. The active ingredient of the drug is glucosamine. In vit...
|
